Journal of Ophthalmology / 2009 / Article / Tab 2

Clinical Study

Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema

Table 2

Changes in mean BCVA and CMT for each group. FU: follow up, BCVA: best corrected visual acuity, CMT: central macular thickness.

Pegaptanib Sodium injection groupCombined treatment GroupMacular Laser Photocoagulation group

Mean FU (months) 6 . 4 1 1 . 9 7.3
Total injections 2 7 2 5
Repeat treatments/ eye 1 0 / 1 3 9 / 1 2
Mean BCVA (LogMAR)-Last FU 0 . 5 ± 0 . 4 ( 9 5 % C I = 0 . 2 , 0 . 7 ) 0 . 3 ± 0 . 2 ( 9 5 % C I = 0 . 2 0 . 4 ) 0 . 3 ± 0 . 3 ( 9 5 % C I = 0 . 1 6 , 0 . 4 5 )
Mean CMT-Last FU 362.2 ± 122.9 (95% CI = 293.3, 431.2) 3 4 8 . 6 ± 6 8 . 5 ( 9 5 % C I = 3 0 8 . 6 , 3 8 8 . 6 ) 3 1 5 . 8 ± 8 7 . 2 ( 9 5 % C I = 2 7 0 . 2 , 3 6 1 . 4 )
Mean BCVA (LogMAR) change 0 . 1 6 ± 0 . 1 5 ( 9 5 % C I = 0 . 2 5 , 0 . 0 8 ) 0 . 0 6 ± 0 . 1 4 ( 9 5 % C I = 0 . 0 2 5 , 0 . 1 3 ) 0 . 0 3 ± 0 . 1 3 ( 9 5 % C I = 0 . 0 4 , 0 . 0 9 )
Mean CMT change 1 4 6 . 7 7 ± 9 3 . 9 ( 9 5 % C I = 1 9 9 . 4 , 9 4 . 1 ) 7 1 . 6 7 ± 1 0 5 . ( 9 5 % C I = 1 3 3 , 1 0 . 3 ) 1 9 . 2 ± 5 4 . 2 ( 9 5 % C I = 4 7 . 5 , 9 . 1 )

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.